Stockwinners Market Radar for September 11, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:11 EDT Pan American Silver reports mineral reserves and resources as of June 30th - Pan American Silver reports its estimated mineral reserves and mineral resources as at June 30, 2024. Proven and probable mineral reserves are estimated to contain approximately 468.0 million ounces of silver and 6.9 million ounces of gold. Measured and indicated mineral resources (excluding proven and probable reserves) are estimated to total approximately 1,148.0 million ounces of silver and 15.5 million ounces of gold. Inferred mineral resources are estimated to total approximately 366.0 million ounces of silver and 9.4 million ounces of gold. The updated mineral reserves and mineral resources estimates are reported net of the sales of the MARA, Agua de la Falda and Morococha properties, as announced in the Company's news release dated July 31, 2023. The divestment of these non-core, non-producing assets is largely responsible for a decrease in mineral reserves and mineral resources compared to 2023. "Our exploration efforts have successfully replaced mine production and expanded mineral reserves at Jacobina, La Colorada, Huaron and Minera Florida. In addition, infill and extensional drilling at the Jacobina mine has increased inferred mineral resources by over 1.2 million ounces of gold, highlighting the significant exploration potential of the deposit and the opportunity to replace mineral resources and mineral reserves in the future," said Christopher Emerson, Pan American's Vice President of Exploration and Geology.

20:06 EDT Cathie Wood's ARK Investment bought 511K shares of Personalis today

18:52 EDT Norfolk Southern names Mark George as new CEO; affirms FY24 guidance - Norfolk Southern "announced that the Norfolk Southern Board of Directors has by unanimous vote of the independent directors appointed Mark R. George, the company's Executive Vice President and Chief Financial Officer, as President and Chief Executive Officer, effective immediately. George will also join the Norfolk Southern Board. George's appointment follows the Norfolk Southern Board's unanimous decision to terminate Alan H. Shaw for cause, effective immediately. This change in leadership comes in connection with preliminary findings from an ongoing investigation that determined Shaw violated company policies by engaging in a consensual relationship with the company's Chief Legal Officer. Shaw's departure is unrelated to the company's performance, financial reporting and results of operations. Norfolk Southern also announced that Nabanita C. Nag has been terminated from her roles as Executive Vice President Corporate Affairs, Chief Legal Officer & Corporate Secretary, effective immediately, in connection with the preliminary findings of the Board's ongoing investigation. Norfolk Southern reaffirms its full-year 2024 guidance provided on July 25, 2024, in conjunction with its second quarter 2024 financial results."

18:30 EDT T-Mobile director sells $54M in common stock - In a regulatory filing, T-Mobile disclosed that its director Raul Claure sold 275K shares of common stock on September 9-11 in a total transaction size of $54M.

18:27 EDT Roblox chief product officer Bronstein sells 40,739 class A shares - In a regulatory filing, Roblox chief product officer Manuel Bronstein disclosed the sale of 40,739 class A common shares of the company on September 9 at a price of $45 per share.

18:12 EDT Civeo board renews share repurchase authorization - Civeo Corporation announced that its Board of Directors has renewed its share repurchase authorization for the company to repurchase up to 5% of its total common shares outstanding over the next twelve months. Civeo may repurchase shares through open market repurchases and/or privately negotiated transactions, and intends to fund repurchases through cash on hand and cash generated from operations.

17:54 EDT Rexford Industrial CFO Clark sells 14,185 common shares - In a regulatory filing, Rexford Industrial Realty CFO Laura Clark disclosed the sale of 14,185 common shares of the company on September 10 at a price of $50.1475 per share.

17:27 EDT RTX-Lockheed Martin JV awarded $124.14M Army contract modification - Raytheon/Lockheed Martin Javelin JV was awarded a $124.14M modification to a contract for Lightweight Command Launch Units. Work will be performed in Tucson, Arizona, with an estimated completion date of May 31, 2028. FY24 procurement of ammunition, Army funds and Foreign Military Sales funds in the amount of $124.14M were obligated at the time of the award. Army Contracting Command is the contracting activity.

17:21 EDT RTX awarded $1.2B Air Force contract modification - Raytheon has been awarded a $1.2B firm-fixed-price, incentive modification to a previously awarded contract for Advanced Medium Range Air-to-Air Missile, or AMRAAM, Production Lot 38. This modification adds additional production of the AMRAAM missiles, AMRAAM telemetry system, initial and field spares, and other production engineering support hardware and activities. Work will be performed in Tucson, Arizona, and is expected to be completed by December 31, 2028. This contract involves Foreign Military Sales to Bahrain, Bulgaria, Canada, Finland, Germany, Hungary, Italy, Japan, Norway, Switzerland, Ukraine, and United Kingdom. Air Force Life Cycle Management Center is the contracting activity.

17:07 EDT CN Energy receives noncompliance notification from Nasdaq - CN Energy announced that on September 6, the company received a letter from the Listing Qualifications Department of Nasdaq notifying the company that it is currently not in compliance with certain requirements under the relevant Nasdaq Listing Rules.

16:53 EDT 23andMe CEO 'open to consider 3rd party takeover proposals' - In a 13/D/A filing, the company states: "On September 9, 2024, in response to requests from the Special Committee, Ms. Wojcicki notified the members of the Special Committee that Ms. Wojcicki would be open to considering third party takeover proposals for the Issuer. Ms. Wojcicki continues to evaluate and negotiate a transaction to acquire all of the Issuer's outstanding shares of common stock not owned by her or her affiliates or any other stockholders she invites to "roll-over" their current equity shares." NOTE: On August 1st, 23and Me also stated: "23andMe Holding, has received a preliminary non-binding indication of interest from Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, to acquire all of the outstanding shares of 23andMe not owned by her or her affiliates or any other stockholder that she invites to roll over their shares for cash consideration of $0.40 per share of Class A Common Stock or Class B Common Stock. Ms. Wojcicki announced the Proposal on July 31, 2024 in a Schedule 13D filing with the Securities and Exchange Commission. The Special Committee previously formed by the Board of Directors of 23andMe is carefully reviewing and evaluating the Proposal and is committed to acting in the best interests of 23andMe and its shareholders."

16:34 EDT iSpecimen announces 1-for-20 reverse stock split - iSpecimen announced that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-20. The reverse stock split will become effective at 4:30 p.m. Eastern Time on September 13 and the Company's common stock will begin trading on a split-adjusted basis when the market opens on September 16, 2024. The Company's common stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "ISPC." The new CUSIP number for the Company's common stock following the reverse stock split will be 45032V207. At the Company's annual meeting of stockholders held on July 19 the stockholders approved a proposal to amend the Company's Fourth Amended and Restated Certificate of Incorporation to effect a reverse stock split in the range of 1-for-10 to 1-for-20, with the final ratio to be determined by the Board of Directors On August 19, 2024, the Board approved a 1-for-20 reverse stock split.

16:31 EDT W. R. Berkley declares special dividend of 25c per share - The dividend is payable on September 30, 2024 to stockholders of record at the close of business on September 23, 2024.

16:25 EDT Viper to acquire subsidiaries from Tumbleweed for $461M in cash, 10.1M units - Viper Energy (VNOM), a subsidiary of Diamondback Energy (FANG), announced it and its operating subsidiary Viper Energy Partners have entered into a definitive purchase and sale agreement to acquire certain mineral and royalty interest- owning subsidiaries of Tumbleweed Royalty in exchange for $461M of cash and approximately 10.1M OpCo units, subject to customary adjustments. The cash portion of this transaction is expected to be funded through a combination of cash on hand, borrowings under the company's credit facility, and proceeds from one or more capital markets transactions, subject to market conditions and other factors. The issuance of OpCo units will be accompanied by the grant of an option to purchase an equal number of shares of Class B common stock of the company. The purchase agreement also includes a potential additional payment in Q1 2026 of contingent cash consideration of up to $41M, based on the average 2025 West Texas Intermediate, or WTI, price. This transaction is expected to close in early Q4, subject to customary closing conditions. The company also announced that it previously closed two related acquisitions. On September 3, OpCo completed the acquisition of certain mineral and royalty interest-owning entities from Tumbleweed-Q Royalty Partners and MC Tumbleweed Royalty for a combined $189M of cash consideration, plus potential additional payments in Q1 2026 of contingent cash consideration of up to an aggregate of $9M, based on the average 2025 WTI price. These transactions were funded with a combination of cash on hand and borrowings under the company's credit facility.

16:22 EDT Artisan Partners reports preliminary August AUM $166.2B - Artisan Partners Asset Management reported that its preliminary assets under management or AUM, as of August 31 totaled $166.2B. Artisan Funds and Artisan Global Funds accounted for $80.1Bof total firm AUM, while separate accounts and other AUM1 accounted for $86.1B.

16:16 EDT Community Health Chief Medical Officer Simon to retire - Community Health Systems announced that Lynn Simon, MD, President, Healthcare Innovation and Chief Medical Officer, will retire from her current executive management position at the end of the year and transition into a consulting arrangement effective January 1, 2025. Under the terms of her consulting agreement, Dr. Simon will continue to advise the Company's management team regarding innovation in healthcare, and will continue to identify, evaluate and facilitate potential new partnerships and emerging capabilities for the organization.

16:16 EDT Redwood Trust raises quarterly dividend by 6.25% to 17c per chare - The dividend is payable on September 30, 2024 to stockholders of record on September 23, 2024.

16:09 EDT Rumble announces new concurrent live viewers record during presidential debate - Rumble announced that it broke several records during Tuesday night's American presidential debate between former President Donald Trump and Vice President Kamala Harris. According to Streams Charts, Rumble logged a record for concurrent live viewers on the platform, as well as new records for the number of concurrent creator streams and peak bandwidth consumption. Streams Charts showed that Rumble hit a peak of 1,044,513 concurrent live viewers during the debate, while also topping one thousand concurrent live streams. The company also set a new bandwidth throughput record on its own content delivery network.

16:09 EDT Build-A-Bear adopts buyback program for up to $100M - Build-A-Bear Workshop announced that its Board of Directors has authorized a new share repurchase program of up to $100 million and declared a quarterly cash dividend of $0.20 per share on the issued and outstanding common stock of the company. The dividend will be paid on October 10, 2024, to all stockholders of record as of September 26, 2024. On August 30, 2022, Board of Directors authorized a $50 million stock repurchase program and as of September 11, 2024, the Company had utilized approximately $44 million of that amount to repurchase over 1.9 million shares at an average price of $23.05 per share. The Board of Directors terminated this program when it adopted the new stock purchase program. Under the new stock repurchase program, the Company is authorized to purchase up to $100 million of its common stock in the open market, through privately negotiated transactions, or pursuant to one or more 10b5-1 plans.

16:07 EDT Methode Electronics declares 14c per share dividend - Methode Electronics announced that its board of directors has declared a quarterly dividend of $0.14 per share to be paid on November 1 to common stockholders of record at the close of business on October 18.

16:06 EDT Merchants Bancorp appoints Sean Sievers as CFO - Merchants Bancorp appointed Sean Sievers as its new CFO, effective Sept. 9. Most recently, Sievers served as CFO at Rate - formerly Guaranteed Rate -. His career includes leadership roles as CFO of Countrywide's Internet Bank and Retail Origination team, Senior Director at Freddie Mac, CFO of SunTrust's Consumer Banking Division, and CFO of Citibank's Global Mortgage Business. John Macke, the company's current CFO, announced his intent to retire in March. Macke joined Merchants in 2017. Sievers and Macke will share responsibilities until Mr. Macke's official retirement at the end of September.

15:11 EDT Oracle announces zettascale cloud computing clusters accelerated by Nvidia - Oracle (ORCL) announced the first zettascale cloud computing clusters accelerated by the NVIDIA Blackwell (NVDA) platform. Oracle Cloud Infrastructure is now taking orders for the largest AI supercomputer in the cloud-available with up to 131,072 NVIDIA Blackwell GPUs. "We have one of the broadest AI infrastructure offerings and are supporting customers that are running some of the most demanding AI workloads in the cloud," said Mahesh Thiagarajan, executive vice president, Oracle Cloud Infrastructure. "With Oracle's distributed cloud, customers have the flexibility to deploy cloud and AI services wherever they choose while preserving the highest levels of data and AI sovereignty." OCI is now taking orders for the largest AI supercomputer in the cloud-available with up to 131,072 NVIDIA Blackwell GPUs-delivering an unprecedented 2.4 zettaFLOPS of peak performance. The maximum scale of OCI Supercluster offers more than three times as many GPUs as the Frontier supercomputer and more than six times that of other hyperscalers. OCI Supercluster includes OCI Compute Bare Metal, ultra-low latency RoCEv2 with ConnectX-7 NICs and ConnectX-8 SuperNICs or NVIDIA Quantum-2 InfiniBand-based networks, and a choice of HPC storage.

14:21 EDT North American rail traffic up 4.4% for the week ending September 7 - The Association of American Railroads or AAR, reported U.S. rail traffic for the week ending September 7. For this week, total U.S. weekly rail traffic was 479,179 carloads and intermodal units, up 7.3% compared with the same week last year. Total carloads for the week ending September 7 were 222,201 carloads, up 2.2% compared with the same week in 2023, while U.S. weekly intermodal volume was 256,978 containers and trailers, up 12.1% compared to 2023. Five of the 10 carload commodity groups posted an increase compared with the same week in 2023. They included grain, up 4,920 carloads, to 19,552; chemicals, up 3,269 carloads, to 32,669; and petroleum and petroleum products, up 1,033 carloads, to 10,778. Commodity groups that posted decreases compared with the same week in 2023 included coal, down 4,024 carloads, to 63,754; motor vehicles and parts, down 1,248 carloads, to 13,663; and forest products, down 338 carloads, to 7,511. North American rail volume for the week ending September 7 on 9 reporting U.S., Canadian, and Mexican railroads totaled 323,723 carloads, down 0.1% compared with the same week last year, and 334,792 intermodal units, up 9.2% compared with last year. Total combined weekly rail traffic in North America was 658,515 carloads and intermodal units, up 4.4%. North American rail volume for the first 36 weeks of 2024 was 23,874,410 carloads and intermodal units, up 2.5% compared with 2023. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Norfolk Southern (NSC) , Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL), L.B. Foster (FSTR), Wabtec (WAB) and GATX (GATX). Reference Link

13:40 EDT Carrier sees 20%-30% growth in orders QTD in Q3 - At the Morgan Stanley Laguna Conference, Carrier Global CEO David Gitlin said that the company sees orders growth of 20%-30% quarter-to-date in Q3, in part due to data center strength. The executive added that the company is "very pleased" with orders in Q2. Shares of Carrier are up 2% in afternoon trading.

12:31 EDT Solomon doesn't think unwinding credit card unit has been messier than expected

12:30 EDT Goldman Sachs CEO thinks 'we've run the credit card program well'

12:26 EDT Goldman Sachs CEO thinks Fed will take action 'as appropriate'

12:24 EDT Goldman Sachs CEO says still in soft landing camp - Goldman Sachs Chairman and CEO David Solomon is speaking on CNBC.

12:22 EDT Goldman Sachs CEO: Bank stocks have done 'incredibly well' for last 12 months

12:14 EDT NatWest appoints Jonathan Peberdy as CEO of NatWest Markets Plc - NatWest Markets Plc, a wholly-owned subsidiary of NatWest Group, announced in a notice to the London Stock Exchange: "Following the receipt of regulatory approval, Jonathan Peberdy has been appointed as CEO and Executive Director of NatWest Markets Plc, with effect from 1st October 2024. Robert Begbie will step down as both CEO and Executive Director of NWM with effect from the same date. Mr Begbie will continue in his role as CEO of the NatWest Commercial & Institutional franchise."

12:00 EDT Albemarle rises 11.1% - Albemarle is up 11.1%, or $8.69 to $87.31.

12:00 EDT Mesabi Trust rises 27.8% - Mesabi Trust is up 27.8%, or $4.66 to $21.42.

12:00 EDT Rentokil Initial falls -20.6% - Rentokil Initial is down -20.6%, or -$6.50 to $25.10.

11:52 EDT TC Biopharm (Holdings) PLC - ADR trading resumes

11:38 EDT New Jersey Resources raises dividend by 7.1% to 45c per share - The board of directors of New Jersey Resources Corporation unanimously approved a 7.1 percent increase in the quarterly dividend rate to 45c per share from 42c per share. The new quarterly rate will be effective with the dividend payable October 1, 2024 to shareowners of record on September 23, 2024.

11:34 EDT BurgerFi files for protection under Chapter 11 - BurgerFi International has filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in order to preserve the value of its brands for all stakeholders. All 144 locations of the Company's two brands throughout the United States, including in Puerto Rico, and in Saudi Arabia, will continue normal, uninterrupted operations. The Chapter 11 filing by the Company includes only the 67 corporate-owned locations of both brands. Franchisee-owned locations of BurgerFi and Anthony's Coal Fired Pizza & Wings are excluded from the bankruptcy proceedings. The Board brought in Carl Bachmann as chief executive officer and Christopher E. Jones, chief financial officer in July 2023 to turnaround and strengthen the brands and operations. Faced with legacy operational challenges, they quickly developed and implemented a strategic plan to address foundational issues including declining same store sales, high employee turnover and a stale menu. As part of the turnaround efforts, the Company initiated a top-to-bottom evaluation of its operations, which is continuing. As a result, the Company has aligned its footprint with current business standards through the closure of 19 underperforming corporate-owned stores and reduced related operating costs. The Company's current platform is primed for success. The Company will be filing customary "first day" motions in the Chapter 11 cases, to ensure normal operations. These motions, subject to court approval, will enable the timely payment of employee wages and benefits, the continuation of customer programs and other relief. The expedited relief being sought by the Company includes permitting guests to continue to use rewards and gift cards at participating locations.

11:07 EDT IonQ, University of Maryland sign $9M agreement to expand partnership - The University of Maryland, an international powerhouse in quantum research and applications, and IonQ announced they have signed a $9M agreement to expand their partnership to provide state-of-the-art quantum computing access at the National Quantum Lab at Maryland. Since its launch in 2021, QLab has provided UMD-affiliated students, faculty, researchers, staff and partners with an unprecedented opportunity to work closely with IonQ's scientists and engineers as they gain experience with industry-leading trapped ion quantum computers. University of Maryland President Darryll J. Pines shared news of the expanded partnership during his remarks at the third annual Quantum World Congress, where he spoke to quantum leaders from across the globe about the university's commitment to growing the vision of "quantum for all", including the development of QLab.

10:04 EDT Vistra partners with Sunrun on residential battery aggregation program - Vistra (VST) announced a new program for homeowners in partnership with Sunrun (RUN) to support grid reliability for Texans. "Through Vistra's flagship retail electricity brand, TXU Energy, the TXU Energy & Sunrun Battery Rewards program will aggregate power stored in residential, solar-connected batteries, forming a virtual power plant to dispatch energy back to the grid when it's needed the most," the company stated.

10:00 EDT Rentokil Initial falls -19.8% - Rentokil Initial is down -19.8%, or -$6.25 to $25.35.

10:00 EDT Oscar Health rises 13.2% - Oscar Health is up 13.2%, or $2.29 to $19.71.

10:00 EDT Mesabi Trust rises 17.5% - Mesabi Trust is up 17.5%, or $2.94 to $19.70.

09:48 EDT SQM rises 11.8% - SQM is up 11.8%, or $4.10 to $38.98.

09:47 EDT Designer Brands falls -15.7% - Designer Brands is down -15.7%, or -91c to $4.90.

09:47 EDT Torrid falls -19.6% - Torrid is down -19.6%, or -$1.31 to $5.37.

09:38 EDT Laser Photonics Corp trading resumes

09:36 EDT Knightscope deploys K5 ASRs at casino, international airport - Knightscope announces two new deployments of its 5th Generation K5 Autonomous Security Robot at a Louisiana casino and an international airport in Texas.

09:34 EDT Vertiv Holdings appoints Frank Poncheri as CHRO - Vertiv has named Frank Poncheri as the new Chief Human Resources Officer, reporting to CEO Giordano Albertazzi. He will lead HR strategy, development and execution, further reinforcing Vertiv's strategic priorities and behaviors. He previously held roles as vice president of HR and corporate integration, divisional HR director, and various other roles during his 10-year tenure with Owens Corning in the United States and Finland.

09:33 EDT Mullen's Bollinger Motors adds Affinity Truck Center to retail network - Mullen Automotive announces that its subsidiary, Bollinger Motors, has named Affinity Truck Center as an official Bollinger Motors dealer. Affinity operates sales locations in Bakersfield and Fresno, California, and service locations in Paso Robles and Salinas, California. Affinity Truck Center is a California Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project certified dealership. The Bollinger B4 chassis cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger's unique chassis design protects the 158-kwh battery pack and components to offer unparalleled capability and safety in the commercial market. The company begins serial production of the B4 on Sept. 16, 2024, and will begin delivering vehicles to customers in October 2024.

09:31 EDT TEN, Ltd. to distribute semi-annual dividend of 90c per share - TEN is pleased to announce that it will distribute to common shareholders a second semi-annual dividend of $0.90 per share following the $0.60 per share paid in July, bringing the total dividend for 2024 operations to $1.50, representing a 50% increase over the amount distributed for 2023 operations. Dividend date to be announced

09:20 EDT Petros executes initial test for app comprehension for STENDRA FDA pathway - Petros Pharmaceuticals announced results of an initial study to determine consumer comprehension of the messaging in its App Technology, which has unique differences from the current Drug Facts Label. Of the 31 objectives, 29 scored greater than90% comprehension Point Estimate 30 scored greater than86.7% comprehension PE, and all scored greater than80% comprehension PE. 21 scored 100% comprehension PE. The results of the study demonstrated that the vast majority of communications were well understood by the patients in the study. The App Comp study evaluated consumer understanding of 31 distinct messages that appeared either on a desktop or a mobile device. The expected threshold of understanding was 90%, of which only two were evaluated lower, as scored by PE. The results of this study, while supportive as a standalone study of the functionality of the App Technology, were designed to provide guidance to the Company in connection with the development of a larger-scale App Comp with a larger patient population, estimated to include about 400 patients. The Company expects to receive results from the larger study, which is currently underway, by Q4 2024.

09:16 EDT Freight Technologies secures win with Bayer - Freight Technologies (FRGT) announced its selection by Bayer CropScience (BAYRY), a division of Bayer AG, as a key logistics provider for the 2025 season. Following a Request for Proposal process, Fr8App has been awarded six essential cross-border lanes to provide truckload services for Bayer's various business units in the United States.This strategic win marks a significant step forward for Fr8Tech as it continues to advance its cross-border over-the-road offering in the competitive logistics market. Bayer CropScience selected Fr8App to support its key goals of supplier consolidation, cost optimization, cross-divisional synergies, and enhanced carrier performance. Aligned with Bayer's mission, Fr8App's role will focus on facilitating seamless and secure transportation across the US-Mexico border, ensuring timely and reliable delivery of Bayer's agricultural products.

09:07 EDT PureCycle announces financing transaction, Ironton production update - PureCycle entered into a series of transactions with Sylebra Capital Management and Samlyn Capital to raise gross proceeds of $90 million. PureCycle anticipates that the transactions will close on September 13, 2024. The transactions include: An issuance of $50 million of Series A, Preferred Stock with a three-year maturity and an 8% return Common stock sale of 8.5 million shares at a price of $4.69 per share for total net proceeds of $40 million The issuance of warrants to purchase 5 million shares of common stock, each exercisable at a price of $11.50 per share with an expiration of December 1, 2030 The extension of Sylebra Capital's $200 million line of credit to March 31, 2026. The capital raised is expected to enable PureCycle to continue executing on its plan to bring its world leading purification process to the market. This significant investment by Sylebra Capital Management and Samlyn Capital, LLC in PureCycle underscores the participating investors' confidence in the company's technology and leadership position in the emerging recycled polypropylene market. The preferred stock portion of this deal allows the company to raise a significant portion of additional capital without dilution to equity holders. The Company also provided several updates on its flagship purification facility in Ironton, Ohio. The Company completed the installation and commissioning of the modifications to the co-product two removal system. The Company has placed it into service and will continue to optimize and streamline the removal over the coming weeks. This new system, when fully operational, and combined with the Company's feed-sorting efforts, will allow the Company to remove the CP2 bottleneck from its production constraints. Beginning in early September, the Ironton Facility turned its focus toward production and has been making meaningful progress against the Company's third quarter goals. The Company is pleased to report that it has already achieved feed rates of over 10,000 pounds per hour and has twice processed more than 200,000 pounds of feedstock in one day. On the commercialization front, the Company continues to make progress with its compounding strategy, customer sampling efforts, initial sales in Q3, and the plan for increased revenues in Q4. The Company has compounded approximately 500,000 pounds to date, with another one million pounds planned for September, and over three million pounds per month planned for the fourth quarter. The Company expects the majority of this material to be sourced into the fiber market following the Company's early successes with these applications.

09:05 EDT Perfect announces partnership with Perfect Corp. - ReVive announced a partnership with Perfect, a leader in beauty tech solutions. This pioneering initiative harnesses the power of AI technology, and utilizes data derived from ReVive's skincare clinical trials. Together, the two are developing a broad group of model imagery that illustrates the benefits of ReVive Skincare's products. This collaborative effort is a first of its kind and interactive solution for shoppers eager to make well-informed decisions, marking a significant advancement in skincare. This partnership is planned to launch in September 2024, with imagery and results available on ReViveSkincare.com and select retail partners.

09:05 EDT Electromed announces $5M share repurchase program - Electromed announced that effective as of September 11, its board of directors authorized the repurchase of up to $5M of Electromed common stock. The new authorization follows the exhaustion of Electromed's previous share repurchase authorization in the fourth quarter of fiscal 2024, as previously reported. The timing and amount of share repurchases pursuant to the authorization, if any, will be determined by management based on market conditions and other considerations. "I am pleased to announce Electromed's next share repurchase authorization, which follows the recent announcement of our record performance in fiscal 2024, and the successful completion of our previous repurchase authorization during Q4," said Jim Cunniff, President, and Chief Executive Officer. "Electromed's revenue growth and profitability profile are driving strong free cash flow, providing us with the flexibility to opportunistically provide incremental value to shareholders while also continuing to invest in the business. This new repurchase authorization reflects the confidence the board and management team have in achieving future growth as well as the belief that our stock has been undervalued after continued delivery of strong financial results.

09:03 EDT AIM ImmunoTech completed a clinical patient data analysis on AMP-518 - AIM ImmunoTech announced that an analysis of the complete clinical patient data from the AMP-518 clinical trial supported the Company's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for AIM's planned follow-up clinical trial. A clear signal of significant potential was observed in Ampligen-treated subjects with a baseline 6MWT less than 205 meters, who saw a mean improvement of 139 meters, compared to a mean improvement of 91 meters in the corresponding part of the group who received the placebo. AIM therefore believes that any future trial design should focus on Ampligen's therapeutic potential for subjects whose Long COVID-related fatigue can be categorized as moderate or worse.

09:02 EDT AT&T signs new agreement with Unsupervised - Unsupervised announced the signing of a new agreement with AT&T. This agreement builds upon a successful ongoing collaboration where Unsupervised's AI-powered Data Analyst software has identified over one-hundred million dollars' worth of opportunities which could be deployed across a variety of business units at AT&T. As part of this new agreement, AT&T plans to use Unsupervised's AI Data Analysts in a wider capacity over the next year to analyze a variety of internal data sources to provide natural language query answers, AI-generated insights, and predictions to AT&T employees. Unsupervised's cutting-edge AI technology automates complex data analysis-traversing vast datasets to uncover valuable patterns and communicate key findings. With the ability to answer queries at lightning speed, retain data relationships, and continuously learn, Unsupervised's AI Data Analysts give companies like AT&T new tools to leverage their data and force multiply their analytics efforts.

09:01 EDT CleanSpark to acquire seven bitcoin mining facilities - CleanSpark announced it has entered into definitive agreements to acquire seven bitcoin mining facilities and certain associated land in the Knoxville, Tennessee, area for total cash payments of $27.5M, or approximately $324,000 per megawatt. This acquisition builds on the Company's strategy of securing high-quality infrastructure opportunities at market-leading valuations. The Company anticipates closing at each of the sites on or before September 25, 2024. The operating hashrate of the combined facilities is anticipated to result in 5 exahashes per second, or EH/s, once the latest generation S21 pro miners are installed, increasing the Company's current hashrate by over 22%. The miners required for this expansion have recently arrived and will be installed promptly upon the closing of each site. The seven sites total 85 MW and range in size from 10 MW to 20 MW.

08:58 EDT PharmAla to terminate agreement with Red Light Holland - PharmAla is disclosing that the Company initiated procedures to terminate its agreement with Red Light Holland, and that said contract was concluded on September 3, 2024.

08:56 EDT LPL Financial: Apex Private Wealth joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Brett Howard, Marco Rivera, Brooks Crissey, Henry "Hank" DesJardins and Ryan Mason have joined LPL Financial's broker-dealer, RIA and custodial platforms. They reported serving approximately $650 million in advisory, brokerage and retirement plan assets, and join LPL from Ameriprise Financial. Founded in 2017 by Howard and DesJardins, the Apex team has since expanded into a full-service ensemble practice that leverages the diverse backgrounds and knowledge of each advisor to provide clients with a comprehensive range of financial planning and investment management services. Based in Santa Rosa, Calif., the team specializes in tax planning, retirement planning, estate planning, wealth preservation, charitable giving, insurance and responsible investing for high-net-worth individuals, families and businesses.

08:45 EDT Catheter Precision reports first purchase order for LockeT in Pacific Northwest - Catheter Precision announced its first purchase order from the pacific northwest territory. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT. The newest purchase order comes from the MultiCare Health System. The MultiCare Health System includes of 300 specialty care locations and twelve hospitals throughout Washington State, Idaho and Oregon.

08:43 EDT Hudson Technologies announces collaboration with LG Air Conditioning - Hudson Technologies has announced its collaboration with LG Air Conditioning Technologies for the supply of Hudson's EMERALD Refrigerants to LG's customer base. The collaboration underscores the commitment of both companies to responsible and sustainable refrigerant management practices and highlights the ongoing industry transition to the use of reclaimed refrigerants.

08:41 EDT Femasys secures distribution partnerships for commercialization of FemaSeed - Femasys announces that the Company has secured strategic distribution partnerships for its CE-marked products, including FemaSeed and FemVue in Spain. Comercial Medico Quirurigca, will distribute the products in northern Spain and Durgalab will distribute them in the south. Spain is the first EU country where the Company has identified distributors and began marketing its products.

08:39 EDT iCoreConnect appoints Yvonne Hyland to board of directors - iCoreConnect has announced the appointment of Yvonne Hyland to its Board of Directors. Her impressive career includes key roles at SAP and Gartner, as well as founding and scaling several technology product and service companies, culminating in successful exits. In addition to her entrepreneurial endeavors, Ms. Hyland has also served as a venture capital operator.

08:38 EDT 3D Systems announces FDA provided clearance for TOTAL ANKLE - 3D Systems announced the Food and Drug Administration, FDA, has provided 510(k) clearance for TOTAL ANKLE Patient-Matched Guides to be used with Smith+Nephew's SALTO TALARIS Total Ankle Prosthesis and CADENCE Total Ankle System. The products feature individualized pre-surgical planning and a patient-specific 3D-printed instrument set that ensures accurate implant alignment and sizing for tailored total ankle replacement surgery. The collaboration between 3D Systems and Smith+Nephew, the global medical technology company, achieved these patient-matched solutions that enable surgeons to prepare the bony anatomy of the tibia and talus for placement of implants intended to restore proper function of the ankle joint. These patient-matched guides are engineered and manufactured using 3D Systems' VSP surgical planning solutions that combine best-in-class digital workflows with the industry's broadest additive manufacturing portfolio of printers and materials.

08:36 EDT Omniq secures over $1M in new purchase orders - OMNIQ announced the receipt of new purchase orders totaling over $1 million from a long-term bioscience customer with whom it has maintained a strategic partnership for over two decades. These orders represent the latest phase in the customer's technological refresh, including the replacement of legacy equipment and the introduction of cutting-edge scanning technology.

08:35 EDT Nano Nuclear Energy signs agreement with GNS to produce HALEU solution - NANO Nuclear Energy announced it has signed an agreement with GNS Gesellschaft fur Nuklear-Service mbH to undertake a wide-ranging project to produce an optimized HALEU transportation system solution based on NANO Nuclear's exclusively licensed fuel transportation basket design. The agreement encompasses a study for the transport of multiple HALEU nuclear fuel types, including uranium oxide, TRISO particles, uranium-zirconium hydride, uranium mononitride, and salt fuel for molten salt reactors.

08:34 EDT AbbVie's Allergan Aesthetics launches Botox for MMP in China - Allergan Aesthetics, an AbbVie company, announced that Botox Cosmetic is now available for the treatment of masseter muscle prominence in China. The masseter is one of the muscles in the lower face involved in chewing, and prominence of the masseter muscle can result in a wide and square lower face shape. Botox Cosmetic was recently approved for the temporary improvement in the appearance of marked to very marked MMP in adults by the China National Medical Product Administration. Botox Cosmetic is the first neurotoxin approved in China for MMP and offers the established dosing, robust clinical evidence and physician training that comes with on-label treatment.

08:32 EDT Allison Transmission partners with Cummins on new electric hybrid drivetrain - Allison Transmission (ALSN) is pleased to announce its most recent collaboration with Cummins (CMI) where the companies will integrate and certify a Cummins B-Series engine with the Allison eGen Flex electric hybrid propulsion system for the transit market. The integration will meet the EPA's "Greenhouse Gas Emissions Standards for Heavy-Duty Vehicles - Phase 3" and provide a reliable low emission propulsion solution in 2027 and beyond.

08:19 EDT Genetic Technologies invited to join CancerIQ online platform - Genetic Technologies has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ has shown, in real-world breast imaging settings, that genetic testing uptake is increased when their platform is integrated into the operational pipeline within the imaging center. Similarly, clinics using CancerIQ have also showed an increase in identification of atrisk adults allowing the clinics to prioritize patients for preventive cancer screenings. Until now, the CancerIQ offerings have been limited to traditional risk assessment models and standard germline testing panels for the assessment of hereditary risk. The inclusion of the geneType Risk Assessment Test portfolio supports CancerIQ's expansion into primary preventive care where the missions of both companies overlap. GENE and CancerIQ are both dedicated to enabling healthcare providers to assess patients' comprehensive risk in order to personalize cancer prevention efforts. GeneType will be CancerIQ's first lab partner solely focused on polygenic-integrated clinical risk prediction. GeneType's focus has always been population healthcare, but until recently healthcare systems have been largely concentrating on hereditary cancer risk. With the integration of geneType into the CancerIQ platform, healthcare systems have the opportunity to engage in polygenic-integrated clinical risk assessment for the general population across nine major diseases spanning cancer and cardiometabolic disease.

08:18 EDT OS Therapies announces efficacy, safety data for ovarian cancer candidate - OS Therapies announced data in animal models of ovarian cancer for its first therapeutic candidate developed based upon its proprietary tunable Antibody Drug Conjugate platform. The first therapeutic candidate leverages a folate receptor alpha targeting small molecule combined with hexa-exatecan payloads linked together with the Company's proprietary silicone linker technology, SiLinker. The data generated showed strong antitumor activity in the KB and IGROV-1 mouse models of ovarian cancer. Taken together, the data provide compelling preclinical proof of concept that the Company's SiLinker platform can be used to develop new therapeutic tADC-based drug candidates that can improve the safety and/or efficacy of ADC combinations currently on the market or in development, in addition to creating new intellectual property for competitive and life cycle management purposes. OST-tADC technology is centered around the Company's proprietary next-generation tunable Antibody Drug Conjugate platform. This advanced technology incorporates pH-sensitive silicon-based linkers, trademarked as SiLinkers, which can release multiple therapeutic agents selectively within the tumor and tumor microenvironment, which experiences lower pH levels than the rest of the body. This approach aims to maximize the therapeutic effects while minimizing damage to healthy cells. KB tumor growth model: In this animal model, animals implanted with the KB tumor cell line were treated at Day 4, Day 8 and Day 12 with either OST-tADC-FRA-H or vehicle control. At Day 20, FRA-H treated animals demonstrated an average tumor volume of 10mm3 as compared with 1000 mm3 for the untreated animals. At Day 40 OST-tADC-FRA-H treated animals had no evidence of tumor growth, whereas control animals had expired. IGROV-1 tumor growth model: In this animal model, animals implanted with the IGROV-1 tumor cell line were treated with either OST-tADC-FRA-H or vehicle control. At Day 50, the OST-tADC-FRA-H treated animals had an average tumor size of 40mm3 as compared animals treated placebo who had an average tumor size of 400 mm3; Bodyweight Comparison: Animals treated with OST-tADC-FRA-H at Day 1 and Day 7 demonstrated no loss in bodyweight as compared with control animals.

08:15 EDT Allegro MicroSystems introduces two new XtremeSenseTMR sensors - Allegro MicroSystems announced two new XtremeSenseTMR sensors that streamline high power density designs, provide space and cost savings while improving energy efficiency. Allegro's latest solutions, CT455 and CT456, offer high-bandwidth and low noise that enable precise current measurements for AI data center and automotive powertrain applications.

08:14 EDT Treace Medical will highlight new production innovations at AOFAS meeting - Treace Medical Concepts announced it will highlight new product innovations and present new interim data for the ALIGN3D and Mini3D Lapiplasty clinical studies at the American Orthopaedic Foot & Ankle Society, AOFAS, Annual Meeting 2024 in Vancouver, British Columbia, Canada from September 11-14, 2024. Several current and next-generation technologies will be highlighted at Treace's booth and in surgeon training events at the AOFAS conference, including: Nanoplasty MIS 3D Osteotomy System; IntelliGuide PSI Cut Guides for Lapiplasty and Adductoplasty Procedures; Mini-Adductoplasty Guides; New SpeedPlate Innovations; and Micro-Lapiplasty Minimally Invasive System

08:12 EDT Kornit Digital announces custom screen apparel provider chose Kornit Apollo - Kornit Digital announced yet another custom screen apparel provider has chosen to further expand use of digital production to transform their business with the Kornit Apollo. T-Formation Inc. of Tallahassee is further transitioning large volumes of production from legacy screen-printing lines to the Kornit Apollo.

08:08 EDT IonQ and the University of Maryland in $9M partnership for quantum innovation - IonQ announced an agreement to expand their partnership to provide state-of-the-art quantum computing access at the National Quantum Lab at Maryland or QLab. QLab provides UMD-affiliated students, faculty, researchers, staff and partners with an unprecedented opportunity to work closely with IonQ's scientists and engineers as they gain experience with industry-leading trapped ion quantum computers. UMD's investment in quantum spans over 35 years and has produced a world leading concentration of quantum expertise - including Nobel Laureate Dr. William Phillips. The University's 10 quantum-focused centers have over 200 researchers who have produced 200+ publications annually, and graduated 100+ quantum-focused physics PhDs in the last decade.

08:06 EDT iRhythm received regulatory approval from Japanese PMDA for Zio ECG system - iRhythm Technologies announced that it has received regulatory approval from the Japanese Pharmaceutical and Medical Device Agency, PMDA, for the Zio fourteen-day, long-term continuous ECG monitoring system. With regulatory approval in hand, iRhythm intends to work towards a reimbursement decision for the Zio ECG monitoring system with the Japanese Ministry of Health, Labour, and Welfare, MHLW. "With the strong support from our partners at the Japanese Heart Rhythm Society, we are thrilled to receive this approval from the Japanese PMDA as a testament to iRhythm's commitment to innovation and the highest standards of quality and performance," said Quentin Blackford, iRhythm President and Chief Executive Officer. "We are very grateful for their diligent review of our Shonin application as we seek to drive better health outcomes and more equitable access for patients around the globe. We look forward to continuing working closely with the MHLW during their market access and reimbursement review of the Zio service."

08:05 EDT Curtiss-Wright announces $100M expansion of share repurchase program - Curtiss-Wright announced a $100M expansion of its 2024 share repurchase program, which is now expected to result in annual share repurchases of $150M in 2024. In addition, the board of directors declared a quarterly dividend of 21c per share on Curtiss-Wright Common Stock, payable October 11 to stockholders of record as of September 27.

08:03 EDT Lineage declares 38c per share quarterly dividend - Lineage announced that its board of directors has declared a prorated quarterly cash dividend of 38c per share for the third quarter of 2024. The dividend is prorated for the period commencing on July 26, the date the company's initial public offering was consummated, and ending on September 30, representing an annualized dividend rate of $2.11 per share. The dividend will be paid on October 21 to shareholders of record of the company's common stock as of the close of business on September 30.

08:01 EDT Actuate Therapeutics announces U.S. FDA granted ODD for elraglusib - Actuate Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, for elraglusib, a novel GSK-3beta inhibitor for treatment of soft tissue sarcoma, STS. "We are pleased to receive the ODD from the FDA, which underscores elraglusib's potential to address the significant yet unmet medical needs for patients with advanced cancers," said Daniel Schmitt, President & Chief Executive Officer of Actuate. "Elraglusib is a leading GSK-3beta inhibitor that has demonstrated a favorable safety profile and antitumor activity across several solid tumors including melanoma, Ewing sarcoma, colorectal and pancreatic cancers. We look forward to the continued development of elraglusib and working closely with regulators to deliver its promise to cancer patients."

07:53 EDT BriaCell reports OS data from Phase 2 study of Bria-IMT in breast cancer - BriaCell Therapeutics announced overall survival data of its Phase 2 clinical study of Bria-IMT in combination with an immune check point inhibitor in late stage metastatic breast cancer. Median overall survival of 15.6 months is reported in BriaCell's most recent patients vs. 6.7-9.3 months for similar patients reported in the literature. These patients are being treated with the same Bria-IMT formulation currently being used in BriaCell's ongoing Phase 3 pivotal study in metastatic breast cancer and represent patients enrolled post-COVID when full study activities resumed. This represents a substantial improvement over BriaCell's 13.4 months median overall survival previously reported in December 2023. The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients who were treated with the Bria-IMT regimen and an immune checkpoint inhibitor. Of these 54 patients, 37 were treated with the Phase 3 formulation and 25 of these were treated post-COVID when full study activities resumed. This data represents an additional six months of follow-up of the survival data presented at the San Antonio Breast Cancer Symposium in December 2023.

07:36 EDT MIRA designates neuropathic pain as primary indication for Ketamir-2 - MIRA Pharmaceuticals has selected neuropathic pain as the initial and primary indication for its novel oral ketamine analog, Ketamir-2. The company has submitted a request for a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration and anticipates the meeting to occur in November 2024. All ongoing regulatory IND-enabling studies are advancing smoothly, and MIRA remains on track to submit its IND to the FDA by the end of this year, with human trials expected to begin in the first quarter of 2025. Selecting neuropathic pain as the primary indication for Ketamir-2 underscores MIRA's commitment to addressing a significant and growing market. Additional studies that further highlighting its versatility and strategic value are planned. These studies will explore Ketamir-2's potential in treating various forms of neuropathic pain such as diabetic neuropathy as well as cancer-and cancer-therapy-induced neuropathic pain. "We see a tremendous opportunity to address the unmet needs in the neuropathic pain market, which is poised to grow substantially over the next decade," said Erez Aminov, Chairman and CEO of MIRA. "Ketamir-2's novel mechanism of action, non-opioid classification, and promising safety profile position it as a breakthrough solution that could redefine pain management for millions of patients."

07:33 EDT Probe Gold advances permitting for Novador project - PROBE GOLD announced that the Company has received the tailored impact statement guidelines for the impact assessment from the Impact Assessment Agency of Canada at the federal level and the guideline for the impact study from the Ministry of the Environment, the Fight Against Climate Change, Wildlife and Parks at the Quebec provincial level. These guidelines clearly outline the requirements Probe must meet to secure permits for the Novador project. The receipt of these guidelines follows Probe's earlier filings of the Initial Project Description and Detailed Project Description with the IAAC at the federal level, as well as the official submission of the "Project Notice" with the MELCCFP at the provincial level. The next step in the permitting process is to initiate the impact study, which IAAC will use, along with other collected information, to create an impact assessment report. At the provincial level, the impact study will have all necessary information for the environmental review and government decisions.

07:13 EDT Quanta Services makes strategic equity investment in Hybar - Hybar LLC, a company building a technologically advanced environmentally sustainable scrap metal recycling steel rebar mill in northeast Arkansas, announced that Quanta Services recently made a strategic equity investment in Hybar. Quanta Services joins Hybar's existing high-profile group of equity investors, including TPG Rise Climate, the dedicated climate investing strategy of TPG's global impact investing platform; Koch Minerals & Trading, a Koch subsidiary specializing in commodity trading and services; and Global Principal Partners, the investment entity used by Hybar's senior management team.

07:10 EDT Sachem Capital completes 20% investment in Shem Creek Capital - Sachem Capital Corp. has acquired a 20% membership interest for $5M in Shem Creek Capital, the third-party management company of the Shem Creek private credit funds. Sachem also has the option to acquire up to an additional 10% membership interest in Shem, by early 2027, at a set valuation. Shem, established in 2008, is a commercial real estate finance company with a focus on providing debt capital solutions to local and regional commercial real estate owners in the Northeastern United States. Shem invests primarily in first mortgage loans secured by commercial real estate assets, notably value-add multifamily, workforce housing, and industrial properties.

07:08 EDT RISE Dispensaries opens 20th Florida location - RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries, announces the opening of its newest location, RISE Jacksonville, on Friday, September 13, 2024. This dispensary marks the 20th RISE location in Florida and the 98th nationwide, continuing Green Thumb's expansion across the state.

07:06 EDT Castle Biosciences: DecisionDx -Melanoma can precise predict SLN positivity risk - Castle Biosciences announced the publication of a new study further demonstrating that DecisionDx-Melanoma can precisely predict sentinel lymph node or SLN, positivity risk to help guide risk-aligned SLNB decisions, potentially reducing the number of unnecessary procedures and increasing the SLNB positivity yield if the procedure is performed. The paper, published in the World Journal of Surgical Oncology and titled "Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort," is available here."Our DecisionDx-Melanoma test has significant clinical utility in helping to rule-out and rule-in SLNB procedures, as this study showed," added Derek Maetzold, president and chief executive officer of Castle Biosciences. "And as demonstrated by data we shared earlier this year from our ongoing prospective, multicenter DECIDE study, patients with low-risk DecisionDx-Melanoma results whose providers use the test to help guide decisions to avoid SLNB surgery still experience good outcomes."1 The results of this study demonstrate that DecisionDx-Melanoma can allow for more precise and personalized management of melanoma patients, improving patient selection for the SLNB surgical procedure and reducing unnecessary procedures and their associated healthcare costs. Moreover, the data provide evidence that DecisionDx-Melanoma can identify patients with a low risk of SLN positivity who may safely forego SLNB, as well as those with a higher risk who may want to consider the surgery.

07:05 EDT Agios Pharmaceuticals announces FDA granted ODD to AG-946 - Agios Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has granted orphan drug designation, ODD, to the company's novel pyruvate kinase, PK, activator tebapivat, AG-946, for the treatment of myelodysplastic syndromes, MDS. "Receiving orphan drug designation for tebapivat in MDS underscores the importance of bringing new oral treatment options to patients suffering from this rare disease," said Sarah Gheuens, M.D., Ph.D., chief medical officer and head R&D at Agios. "We aim to deliver the first oral therapy that addresses anemia due to ineffective erythropoiesis in lower-risk MDS, which affects approximately 75,000-80,000 patients in the U.S. and EU5 and accounts for approximately 70% of MDS cases."

07:03 EDT Regeneron announces new analyses of EYLEA HD Injection - Regeneron Pharmaceuticals announced new analyses of EYLEA HD Injection 8 mg and EYLEA Injection 2 mg will be presented at the Annual Meeting of the European Society of Retina Specialists, EURETINA, in Barcelona from September 19 to 22, 2024. "The presentations at EURETINA reinforce the efficacy and safety profile of EYLEA HD and the ability to extend dosing intervals leading to significant and positive impacts on patients with wet age-related macular degeneration and diabetic macular edema," said Boaz Hirshberg, MD, Senior Vice President, Clinical Development, Internal Medicine at Regeneron. "EYLEA HD continues on its way to becoming the new standard of care for these retinal diseases based on its differentiated clinical profile, and its strong familiarity and satisfaction among retinal specialists."

06:57 EDT Zoomcar partners with Mappls MapmyIndia - Zoomcar announced its partnership with Mappls MapmyIndia, India's digital mapping, geospatial software and location-based IoT company. This collaboration enables users to book a Zoomcar while getting their trips planned with the Mappls app, enhancing the end-to-end travel planning and booking experience.

06:51 EDT ANI Pharmaceuticals, Alimera Sciences merger to close on September 16 - ANI Pharmaceuticals (ANIP) and Alimera Sciences (ALIM) jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16.

06:33 EDT Sanara MedTech and InfuSystem execute U.S. distribution agreement - Sanara MedTech (SMTI) and InfuSystem (INFU), the operational subsidiary of Sanara's joint venture partner InfuSystem Holdings, announced the execution of an exclusive U.S. distribution agreement with, and minority investment in, ChemoMouthpiece. ChemoMouthpiece owns and manufactures a 510 cleared device that uses cryotherapy to reduce the incidence and severity of oral mucositis in patients undergoing stomatotoxic chemotherapy treatments. SI Healthcare Technologies, a 50/50 joint venture between Sanara and InfuSystem, will be the exclusive distributor of ChemoMouthpiece's kits in the U.S. SI Technologies plans to market and distribute the product through InfuSystem to approximately 3,000 cancer centers through InfuSystem's existing sales team. SI Technologies will purchase the product kits from ChemoMouthpiece at a fixed price and pay a royalty on net revenues for the use of the product intellectual property. Sanara invested $5M for a 6.6% ownership position in ChemoMouthpiece. SI Technologies will have a purchase option that expires on January 31, 2029 to purchase the U.S. business of ChemoMouthpiece, including all U.S. intellectual property related to the product. Sanara has drawn $15.5M on its term loan with CRG Servicing, LLC and will fund this investment as part of that draw. Pickwick Capital Partners, LLC, served as the exclusive advisor to ChemoMouthpiece on this transaction.

06:27 EDT Infosys announces collaboration with Clearstream - Infosys announced that it has collaborated with Clearstream, the post-trade services part of Deutsche Borse, an international exchange organization and a provider of market infrastructure. The collaboration supported the successful Generation 2 launch of Clearstream's D7 platform, an innovative digital post-trade platform that allows market participants to issue securities digitally.

06:05 EDT Copa Holdings reports August load factor 85.1% - For August, Copa Holdings' capacity increased by 8.2%, while system-wide passenger traffic increased by 5.8%, compared to 2023. As a result, the system load factor for the month was 85.1%, 1.9 percentage points lower than in August 2023.

06:03 EDT Yunji to implement 1-to-400 ADS ratio change - Yunji announced that it plans to change the ratio of its American Depositary Shares, or ADSs, to its Class A ordinary shares, par value $0.000005 per share, from the current ADS Ratio of one ADSs to 100 Class A ordinary shares to a new ADS Ratio of one ADS to 400 Class A ordinary shares. A post-effective amendment to the ADS Registration Statement on Form F-6 will be filed with the SEC to reflect the change in the ADS Ratio. The company anticipates that the change in the ADS Ratio will be effective on or about September 13, subject to the effectiveness of the post-effective amendment to the ADS Registration Statement on Form F-6 on or before that date.